Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

148.79USD
4:00pm EDT
Price Change (% chg)

$1.93 (+1.31%)
Prev Close
$146.86
Open
$148.18
Day's High
$149.91
Day's Low
$147.27
Volume
754,405
Avg. Vol
896,245
52-wk High
$149.91
52-wk Low
$66.89

CELG.OQ

Chart for CELG.OQ

About

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in... (more)

Overall

Beta: 0.80
Market Cap (Mil.): $60,400.00
Shares Outstanding (Mil.): 411.28
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 40.97 47.13 37.76
EPS (TTM): 3.58 -- --
ROI: 16.58 -2.58 18.76
ROE: 27.28 -2.66 19.59
Search Stocks

Celgene raises full-year outlook on strong cancer drug sales

- Biotechnology firm Celgene Corp raised its full-year earnings forecast for the second time in three months after it reported a quarterly profit above analysts' estimates, as its cancer drugs, Revlimid and Abraxane, continued to post strong sales growth.

25 Jul 2013

Celgene profit tops estimates on strong cancer drug sales

- Biotechnology firm Celgene Corp reported a quarterly profit above analysts' estimates as demand for its cancer drugs, Revlimid and Abraxane, remained strong, and the company raised its full-year earnings forecast for the second time.

25 Jul 2013

Celgene profit tops estimates on strong cancer drug sales

July 25 - Biotechnology firm Celgene Corp reported a quarterly profit above analysts' estimates as demand for its cancer drugs, Revlimid and Abraxane, remained strong, and the company raised its full-year earnings forecast for the second time.

25 Jul 2013

Celgene to stop blood cancer trial due to high death rates

- Celgene Corp said it will stop a late-stage trial of its blood cancer drug, Revlimid, after it observed a higher number of deaths in elderly leukemia patients taking the drug compared with those on another treatment.

18 Jul 2013

UPDATE 2-Celgene to stop blood cancer trial due to high death rates

* Shares down 2.7 pct (Adds analyst comments, company comments, updates share price)

18 Jul 2013

CORRECTED-Celgene to stop blood cancer trial due to higher death rates

(Corrects paragraph 1 to say the drug was compared to another drug and not a placebo)

18 Jul 2013

Market for Celgene blood cancer drug seen growing after trial

- Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in newly diagnosed blood cancer patients, potentially opening up the path for a wider use of the drug.

11 Jul 2013

UPDATE 2-Market for Celgene blood cancer drug seen growing after trial

* Data can help Revlimid get approved for wider group of patients

11 Jul 2013

Celgene's Revlimid improves survival in blood cancer patients

July 11 - Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in blood cancer patients.

11 Jul 2013

UK cost agency says 'no' to Celgene bone marrow drug

LONDON - Celgene's drug Revlimid is not worth using on Britain's state health service because of uncertainty over whether it can extend the lives of patients with serious bone marrow disorders, the country's cost agency said on Thursday.

10 Jul 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Streetwise Reports
$104.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: TheStreet.com Ratings
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks